| Name | Title | Contact Details |
|---|
Market USA, a full-service financial institution, was originally chartered in 1953 to serve Giant Food employees in the Mid-Atlantic region. Throughout the years our membership has grown to include additional grocery store chains such as Giant of Carlisle, Stop and Shop, and BI-LO, as well as over 80 select employer groups. As a member-owned, not-for-profit cooperative, we exist solely to bring our membership innovative products and services with low loan rates, competitive dividend rates, and low or no fees. Benefits of membership include free checking, a variety of loan and deposit products, mobile services, financial education and counseling, access to thousands of surcharge-free ATMs, discounts on insurance products, and much more. Our top priority is our members financial success. Members are our shareholders and each member has one vote. In addition, we are governed by a volunteer board of directors who look out for the best interest of members, not stockholders.
Atlanta Design Group (ADG) is a Full-Service Interior Design Company made up of a group of specialized brands offering numerous products and services supporting the interior design and design-build trades. ADG was organized to meet the needs of the design profession in an ever-changing global market. By diversifying our products and services and providing our clients with a customer experience designed to span the lifetime of the project, ADG is redefining how the design industry conducts business. Atlanta Design Group covers all the bases to include interior design; specialized marketing; furniture and accessories; outdoor living; kitchen & bath; specialty construction products, fine art and framing, lighting solutions and installation and logistics services making your job more streamlined than ever. We are confident that forming a business relationship with our company is the absolute best move you can make towards growing and advancing your business to the next level. Working together, Atlanta Design Group is a single, turnkey source working for you. One Company, One Source, One Solution The Power of One
A Global Development Expedition FOR women, not ABOUT women. Signature Leaders is designed to augment, rather than replace, existing corporate executive leadership development. These are programs for women with the highest potential, to fast-track them into next level leadership. These women are managing large P&Ls, leading transformations across the enterprise or sizeable functional teams, or in that critical "pivot" from managing to leading. We gather these elite leaders from around the world for introspective learning and external connections. Our executive faculty covers our framework of Who You Are, How You Show Up, and How You Relate to Others. Unlike typical seminars or conferences, participants will join the Signature community upon enrollment. This means the opportunities for learning and growth starts prior to, and continues beyond, the immersion session. Signature alumni move forward with an invaluable network of more than 2,300 peers and 250 executive faculty members and advisors who support them throughout their ongoing leadership journey. Why Signature as a name? Because every executive has a unique style and "signature" embedded in the way they lead. Our curriculum focuses on the essential capabilities needed for next level leadership in a way that encourages executives to broaden, not change their own distinct style – the leadership signature that makes them authentic.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.